
## Dusan Ruzic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2656351/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics, 2022, 14, 209.	4.5	26
2	Anticancer evaluation of the selected tetrahydropyrimidines: 3D-QSAR, cytotoxic activities, mechanism of action, DNA, and BSA interactions. Journal of Molecular Structure, 2022, 1257, 132621.	3.6	7
3	Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies. Future Medicinal Chemistry, 2022, 14, 557-570.	2.3	0
4	Bistable Photoswitch Allows in Vivo Control of Hematopoiesis. ACS Central Science, 2022, 8, 57-66.	11.3	18
5	Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics. Journal of Chemical Information and Modeling, 2022, 62, 2571-2585.	5.4	5
6	<i>In silico</i> identification of novel 5-HT <sub>2A</sub> antagonists supported with ligand- and target-based drug design methodologies. Journal of Biomolecular Structure and Dynamics, 2021, 39, 1819-1837.	3.5	12
7	Medicinal chemistry of histone deacetylase inhibitors. Arhiv Za Farmaciju, 2021, 71, 73-100.	0.5	2
8	Fragment-Based Drug Design of Selective HDAC6 Inhibitors. Methods in Molecular Biology, 2021, 2266, 155-170.	0.9	8
9	An Integrative <i>in silico</i> Drug Repurposing Approach for Identification of Potential Inhibitors of SARSâ€CoVâ€2 Main Protease. Molecular Informatics, 2021, 40, e2000187.	2.5	7
10	Design of Dual COX-2 and 5-LOX Inhibitors with Iron-Chelating Properties Using Structure-Based and Ligand-Based Methods. Letters in Drug Design and Discovery, 2021, 18, .	0.7	0
11	Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein. Molecules, 2021, 26, 5300.	3.8	5
12	Structure-based design of selective histone deacetylase 6 zinc binding groups. Journal of Biomolecular Structure and Dynamics, 2020, 38, 3166-3177.	3.5	7
13	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. ACS Medicinal Chemistry Letters, 2019, 10, 863-868.	2.8	6
14	Modulating Protein–Protein Interactions with Visible‣ightâ€Responsive Peptide Backbone Photoswitches. ChemBioChem, 2019, 20, 1417-1429.	2.6	33
15	Combined Ligand and Fragmentâ€based Drug Design of Selective Histone Deacetylase – 6 Inhibitors. Molecular Informatics, 2019, 38, e1800083.	2.5	17
16	In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs. Frontiers in Chemistry, 2019, 7, 873.	3.6	71
17	Quantitative structure-retention relationship of selected imidazoline derivatives on α1-acid glycoprotein column. Journal of Pharmaceutical and Biomedical Analysis, 2016, 127, 101-111.	2.8	14